These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22585665)

  • 1. Growth hormone secretion and its effect on height in pediatric patients with different genotypes of Prader-Willi syndrome.
    Oto Y; Obata K; Matsubara K; Kozu Y; Tsuchiya T; Sakazume S; Yoshino A; Murakami N; Ogata T; Nagai T
    Am J Med Genet A; 2012 Jun; 158A(6):1477-80. PubMed ID: 22585665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtype and growth hormone effects on dysmorphology in Prader-Willi syndrome.
    Oldzej J; Manazir J; Gold JA; Mahmoud R; Osann K; Flodman P; Cassidy SB; Kimonis VE
    Am J Med Genet A; 2020 Jan; 182(1):169-175. PubMed ID: 31782896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Genotype and Previous GH Treatment on Adiposity in Adults With Prader-Willi Syndrome.
    Coupaye M; Tauber M; Cuisset L; Laurier V; Bieth E; Lacorte JM; Oppert JM; Clément K; Poitou C
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4895-4903. PubMed ID: 27662437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic subtypes and phenotypic characteristics of 110 patients with Prader-Willi syndrome.
    Zhang L; Liu X; Zhao Y; Wang Q; Zhang Y; Gao H; Zhang B; Cui W; Zhao Y
    Ital J Pediatr; 2022 Jul; 48(1):121. PubMed ID: 35870983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes.
    Grugni G; Giardino D; Crinò A; Malvestiti F; Ballarati L; Di Giorgio G; Marzullo P
    J Endocrinol Invest; 2011; 34(7):493-7. PubMed ID: 20651469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of molecular classes and growth hormone treatment on growth and dysmorphology in Prader-Willi syndrome: A multicenter study.
    Mahmoud R; Leonenko A; Butler MG; Flodman P; Gold JA; Miller JL; Roof E; Dykens E; Driscoll DJ; Kimonis V
    Clin Genet; 2021 Jul; 100(1):29-39. PubMed ID: 33615449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.
    Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polymorphism in the growth hormone receptor is associated with height in children with Prader-Willi syndrome.
    Park SW; Lee ST; Sohn YB; Kim SH; Cho SY; Ko AR; Ji ST; Kwon JY; Yeau S; Paik KH; Kim JW; Jin DK
    Am J Med Genet A; 2011 Dec; 155A(12):2970-3. PubMed ID: 22052808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index.
    Butler MG; Matthews NA; Patel N; Surampalli A; Gold JA; Khare M; Thompson T; Cassidy SB; Kimonis VE
    Am J Med Genet A; 2019 Sep; 179(9):1826-1835. PubMed ID: 31313492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
    Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
    Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
    J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype and phenotype in patients with Prader-Willi syndrome in Taiwan.
    Lin HY; Lin SP; Chuang CK; Chen MR; Yen JL; Lee YJ; Huang CY; Tsai LP; Niu DM; Chao MC; Kuo PL
    Acta Paediatr; 2007 Jun; 96(6):902-5. PubMed ID: 17537021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Subtype-Phenotype Analysis of Growth Hormone Treatment on Psychiatric Behavior in Prader-Willi Syndrome.
    Montes AS; Osann KE; Gold JA; Tamura RN; Driscoll DJ; Butler MG; Kimonis VE
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
    Fillion M; Deal C; Van Vliet G
    J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment.
    Cadoudal T; Buléon M; Sengenès C; Diene G; Desneulin F; Molinas C; Eddiry S; Conte-Auriol F; Daviaud D; Martin PG; Bouloumié A; Salles JP; Tauber M; Valet P
    Int J Obes (Lond); 2014 Sep; 38(9):1234-40. PubMed ID: 24406482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome.
    Dağdeviren Çakır A; Baş F; Akın O; Şıklar Z; Özcabı B; Berberoğlu M; Kardelen AD; Bayramoğlu E; Poyrazoğlu Ş; Aydın M; Törel Ergür A; Gökşen D; Bolu S; Aycan Z; Tüysüz B; Ercan O; Evliyaoğlu O
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):308-319. PubMed ID: 33565750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uniparental disomy and pretreatment IGF-1 may predict elevated IGF-1 levels in Prader-Willi patients on GH treatment.
    Palmieri VV; Lonero A; Bocchini S; Cassano G; Convertino A; Corica D; Crinò A; Fattorusso V; Ferraris S; Fintini D; Franzese A; Grugni G; Iughetti L; Lia R; Macchi F; Madeo SF; Matarazzo P; Nosetti L; Osimani S; Pajno R; Patti G; Pellegrin MC; Perri A; Ragusa L; Rutigliano I; Sacco M; Salvatoni A; Scarano E; Stagi S; Tornese G; Trifirò G; Wasniewska M; Fischetto R; Giordano P; Licenziati MR; Delvecchio M;
    Growth Horm IGF Res; 2019; 48-49():9-15. PubMed ID: 31487604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.